Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study
Open Access
- 1 May 2017
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Critical Care Medicine
- Vol. 45 (5), 781-789
- https://doi.org/10.1097/ccm.0000000000002321
Abstract
To prospectively validate that the inability to decrease procalcitonin levels by more than 80% between baseline and day 4 is associated with increased 28-day all-cause mortality in a large sepsis patient population recruited across the United States. Blinded, prospective multicenter observational clinical trial following an Food and Drug Administration-approved protocol. Thirteen U.S.-based emergency departments and ICUs. Consecutive patients meeting criteria for severe sepsis or septic shock who were admitted to the ICU from the emergency department, other wards, or directly from out of hospital were included. Procalcitonin was measured daily over the first 5 days. The primary analysis of interest was the relationship between a procalcitonin decrease of more than 80% from baseline to day 4 and 28-day mortality using Cox proportional hazards regression. Among 858 enrolled patients, 646 patients were alive and in the hospital on day 4 and included in the main intention-to-diagnose analysis. The 28-day all-cause mortality was two-fold higher when procalcitonin did not show a decrease of more than 80% from baseline to day 4 (20% vs 10%; p = 0.001). This was confirmed as an independent predictor in Cox regression analysis (hazard ratio, 1.97 [95% CI, 1.18–3.30; p < 0.009]) after adjusting for demographics, Acute Physiology and Chronic Health Evaluation II, ICU residence on day 4, sepsis syndrome severity, antibiotic administration time, and other relevant confounders. Results of this large, prospective multicenter U.S. study indicate that inability to decrease procalcitonin by more than 80% is a significant independent predictor of mortality and may aid in sepsis care.Keywords
This publication has 41 references indexed in Scilit:
- Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trialThe Lancet Infectious Diseases, 2016
- Procalcitonin Kinetics in the First 72 Hours Predicts 30-Day Mortality in Severely Ill Septic Patients Admitted to an Intermediate Care UnitJournal of Clinical Medicine Research, 2015
- Biomarkers for SepsisBioMed Research International, 2014
- Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomesIntensive Care Medicine, 2013
- Procalcitonin to Guide Initiation and Duration of Antibiotic Treatment in Acute Respiratory Infections: An Individual Patient Data Meta-AnalysisClinical Infectious Diseases, 2012
- Procalcitonin for reduced antibiotic exposure in the critical care setting: A systematic review and an economic evaluation*Critical Care Medicine, 2011
- Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008Critical Care Medicine, 2007
- Procalcitonin increase in early identification of critically ill patients at high risk of mortality*Critical Care Medicine, 2006
- A Blueprint for a Sepsis ProtocolAcademic Emergency Medicine, 2005
- Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trialThe Lancet, 2004